Limits...
Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants.

Jones SA, Groome M, Koen A, Van Niekerk N, Sewraj P, Kuwanda L, Izu A, Adrian PV, Madhi SA - PLoS ONE (2013)

Bottom Line: The proportion of children with OPA ≥ 8 for serotypes 9V, 19F and 23F increased significantly following the 3(rd) PCV7-dose to 93.6%; 86.0% and 89.7% respectively.Geometric mean concentrations (GMCs) following the 3(rd) PCV7-dose were higher for all serotypes in this study compared to the historical cohort.The studied PCV7 dosing schedule induced good immune responses, including higher GMCs following the 3(rd-)dose at 9-months compared to when given at 14-weeks of age.

View Article: PubMed Central - PubMed

Affiliation: Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa ; Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Johannesburg, South Africa.

ABSTRACT

Background: The high cost of pneumococcal conjugate vaccine (PCV) and local epidemiological factors contributed to evaluating different PCV dosing-schedules. This study evaluated the immunogenicity of seven-valent PCV (PCV7) administered at 6-weeks; 14-weeks and 9-months of age.

Methods: 250 healthy, HIV-unexposed infants were immunized with PCV7 concurrently with other childhood vaccines. Serotype-specific anti-capsular IgG concentrations were measured one-month following the 1(st) and 2(nd) PCV-doses, prior to and two-weeks following the 3(rd) dose. Opsonophagocytic killing assay (OPA) was measured for three serotypes following the 2(nd) and 3(rd) PCV7-doses. Immunogenicity of the current schedule was compared to a historical cohort of infants who received PCV7 at 6, 10 and 14 weeks of age.

Results: The proportion of infants with serotype-specific antibody ≥ 0.35 µg/ml following the 2(nd) PCV7-dose ranged from 84% for 6B to ≥ 89% for other serotypes. Robust antibody responses were observed following the 3(rd) dose. The proportion of children with OPA ≥ 8 for serotypes 9V, 19F and 23F increased significantly following the 3(rd) PCV7-dose to 93.6%; 86.0% and 89.7% respectively. The quantitative antibody concentrations following the 2(nd) PCV7-dose were comparable to that after the 3(rd) -dose in the 6-10-14 week schedule. Geometric mean concentrations (GMCs) following the 3(rd) PCV7-dose were higher for all serotypes in this study compared to the historical cohort.

Conclusions: The studied PCV7 dosing schedule induced good immune responses, including higher GMCs following the 3(rd-)dose at 9-months compared to when given at 14-weeks of age. This may confer longer persistence of antibodies and duration of protection against pneumococcal disease.

Show MeSH
IgG GMC following a 2-dose primary series and a booster dose of PCV-7.IgG antibody GMC for each of the 7 serotypes following vaccination with PCV-7, administered as a 2-dose primary series, given at 6- and 14-weeks of age, and a booster dose at 40 weeks of age. GMC were measured at baseline, after the first dose (Post PCV1) and second dose (Post PCV2) and also prior to (Pre PCV3) and after (Post PCV3) the booster dose.GMC = Geometric Mean Concentrations, PCV-7= 7-valent Pneumococcal Conjugate Vaccine.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3755982&req=5

pone-0072794-g002: IgG GMC following a 2-dose primary series and a booster dose of PCV-7.IgG antibody GMC for each of the 7 serotypes following vaccination with PCV-7, administered as a 2-dose primary series, given at 6- and 14-weeks of age, and a booster dose at 40 weeks of age. GMC were measured at baseline, after the first dose (Post PCV1) and second dose (Post PCV2) and also prior to (Pre PCV3) and after (Post PCV3) the booster dose.GMC = Geometric Mean Concentrations, PCV-7= 7-valent Pneumococcal Conjugate Vaccine.

Mentions: The vaccine-serotype specific GMCs following each PCV7 dose is shown in Table S1 and Figure 2. There was a 3.48 (serotype 14) to 11.73 (serotype 23F) fold increase in GMCs between the first and second PCV7 doses, which was consistently higher for all serotypes compared to the fold increase between baseline and after the first PCV7 dose; Table S1. The GMCs to all serotypes declined by age of 39.9 weeks when the 3rd PCV7 dose was administered, which was followed by a 4.74 (serotype 14) to 29.25 (serotype 23F) fold- increase in GMC following the 3rd PCV7-dose; Table S1 and Figure 2.


Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants.

Jones SA, Groome M, Koen A, Van Niekerk N, Sewraj P, Kuwanda L, Izu A, Adrian PV, Madhi SA - PLoS ONE (2013)

IgG GMC following a 2-dose primary series and a booster dose of PCV-7.IgG antibody GMC for each of the 7 serotypes following vaccination with PCV-7, administered as a 2-dose primary series, given at 6- and 14-weeks of age, and a booster dose at 40 weeks of age. GMC were measured at baseline, after the first dose (Post PCV1) and second dose (Post PCV2) and also prior to (Pre PCV3) and after (Post PCV3) the booster dose.GMC = Geometric Mean Concentrations, PCV-7= 7-valent Pneumococcal Conjugate Vaccine.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3755982&req=5

pone-0072794-g002: IgG GMC following a 2-dose primary series and a booster dose of PCV-7.IgG antibody GMC for each of the 7 serotypes following vaccination with PCV-7, administered as a 2-dose primary series, given at 6- and 14-weeks of age, and a booster dose at 40 weeks of age. GMC were measured at baseline, after the first dose (Post PCV1) and second dose (Post PCV2) and also prior to (Pre PCV3) and after (Post PCV3) the booster dose.GMC = Geometric Mean Concentrations, PCV-7= 7-valent Pneumococcal Conjugate Vaccine.
Mentions: The vaccine-serotype specific GMCs following each PCV7 dose is shown in Table S1 and Figure 2. There was a 3.48 (serotype 14) to 11.73 (serotype 23F) fold increase in GMCs between the first and second PCV7 doses, which was consistently higher for all serotypes compared to the fold increase between baseline and after the first PCV7 dose; Table S1. The GMCs to all serotypes declined by age of 39.9 weeks when the 3rd PCV7 dose was administered, which was followed by a 4.74 (serotype 14) to 29.25 (serotype 23F) fold- increase in GMC following the 3rd PCV7-dose; Table S1 and Figure 2.

Bottom Line: The proportion of children with OPA ≥ 8 for serotypes 9V, 19F and 23F increased significantly following the 3(rd) PCV7-dose to 93.6%; 86.0% and 89.7% respectively.Geometric mean concentrations (GMCs) following the 3(rd) PCV7-dose were higher for all serotypes in this study compared to the historical cohort.The studied PCV7 dosing schedule induced good immune responses, including higher GMCs following the 3(rd-)dose at 9-months compared to when given at 14-weeks of age.

View Article: PubMed Central - PubMed

Affiliation: Department of Science/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa ; Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Johannesburg, South Africa.

ABSTRACT

Background: The high cost of pneumococcal conjugate vaccine (PCV) and local epidemiological factors contributed to evaluating different PCV dosing-schedules. This study evaluated the immunogenicity of seven-valent PCV (PCV7) administered at 6-weeks; 14-weeks and 9-months of age.

Methods: 250 healthy, HIV-unexposed infants were immunized with PCV7 concurrently with other childhood vaccines. Serotype-specific anti-capsular IgG concentrations were measured one-month following the 1(st) and 2(nd) PCV-doses, prior to and two-weeks following the 3(rd) dose. Opsonophagocytic killing assay (OPA) was measured for three serotypes following the 2(nd) and 3(rd) PCV7-doses. Immunogenicity of the current schedule was compared to a historical cohort of infants who received PCV7 at 6, 10 and 14 weeks of age.

Results: The proportion of infants with serotype-specific antibody ≥ 0.35 µg/ml following the 2(nd) PCV7-dose ranged from 84% for 6B to ≥ 89% for other serotypes. Robust antibody responses were observed following the 3(rd) dose. The proportion of children with OPA ≥ 8 for serotypes 9V, 19F and 23F increased significantly following the 3(rd) PCV7-dose to 93.6%; 86.0% and 89.7% respectively. The quantitative antibody concentrations following the 2(nd) PCV7-dose were comparable to that after the 3(rd) -dose in the 6-10-14 week schedule. Geometric mean concentrations (GMCs) following the 3(rd) PCV7-dose were higher for all serotypes in this study compared to the historical cohort.

Conclusions: The studied PCV7 dosing schedule induced good immune responses, including higher GMCs following the 3(rd-)dose at 9-months compared to when given at 14-weeks of age. This may confer longer persistence of antibodies and duration of protection against pneumococcal disease.

Show MeSH